Davita Inc vs Jumia Technologies AG - ADR — how do they compare? Davita Inc trades at $175.04 (market cap $11.29B), while Jumia Technologies AG - ADR trades at $6.53 (market cap $865.90M). The key difference: Davita Inc is far larger — about 13× Jumia Technologies AG - ADR's market cap, and Davita Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 113 Days and Jumia Technologies AG - ADR for 28 Days on average.
| DVA | JMIA | |
|---|---|---|
Market Cap | $11.29B | $865.90M |
Volume | 582,204 | 1,695,227 |
Sector | Health | Consumer Cyclical |
52-Week High | $240.96 | $14.60 |
52-Week Low | $103.87 | $5.69 |
Typical Hold Time | 113 Days | 28 Days |
Enterprise Value | $24.01B | $831.54M |
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $176.78, down 2.01% today, showing technical bearish signals with price near key support at $175. Fundamentally, the company demonstrates solid earnings performance with three consecutive quarterly beats and attractive valuation metrics including a P/E of 14.98 and P/S of 0.88. Recent expansion of value-based care partnerships with Humana positions the company for continued growth in kidney care services.
The stock presents a compelling value opportunity with analyst consensus target of $235.67 offering 33% upside potential, though investors face risks from regulatory pressures and narrowing profit margins. Warren Buffett's significant ownership (45%) and institutional buying activity provide confidence, but the bearish technical outlook and mixed analyst ratings (43% Buy, 52% Hold) suggest cautious optimism is warranted.
JMIA trades at $6.74, down 0.88% with bearish technical signals. The company shows improving fundamentals with revenue growth to $189M in 2025 and narrowing losses (-$62M net income). Recent $50M capital injection from IFC strengthens the balance sheet while management targets EBITDA breakeven by Q4 2026. Analyst consensus remains bullish with $12 price target despite recent earnings misses.
JMIA presents a turnaround story with operational improvements and path to profitability, but carries significant execution risk. The stock offers substantial upside to analyst targets if the company achieves its breakeven timeline, though persistent losses and competitive pressures remain concerns for investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →